Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPG | Q9Y5X9 | 5/20 | 0.36 |
| ▸ | LPL | P06858 | 4/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.35 |
| ▸ | F11 | P03951 | 1/20 | 0.33 |
| ▸ | P4HB | P07237 | 1/20 | 0.33 |
| ▸ | GSK3A | P49840 | 1/20 | 0.32 |
| ▸ | GSK3B | P49841 | 1/20 | 0.32 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.31 |
| ▸ | KDR | P35968 | 1/20 | 0.31 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30639739 | 1.00 | LIPG (0.36) | LIPGLPLFFAR1F11P4HB | |
| SCHEMBL30639721 | 0.80 | LIPG (0.39) | LIPGLPLFFAR1F11P4HB | |
| SCHEMBL15401262 | 0.80 | LPL (0.39) | LIPGLPLFFAR1F11P4HB | |
| SCHEMBL522165 | 0.80 | LIPG (0.39) | LIPGLPLFFAR1F11P4HB | |
| SCHEMBL21734208 | 0.78 | LPL (0.38) | LIPGLPLFFAR1F11P4HB | |
| SCHEMBL12373176 | 0.78 | LPL (0.44) | LIPGLPLFFAR1F11 | |
| SCHEMBL20361741 | 0.75 | LPL (0.35) | LIPGLPLFFAR1F11P4HB | |
| SCHEMBL20361743 | 0.75 | LPL (0.35) | LIPGLPLFFAR1F11P4HB | |
| SCHEMBL4163085 | 0.74 | FFAR1 (0.40) | LIPGLPLFFAR1F11GSK3A | |
| SCHEMBL975905 | 0.74 | LPL (0.49) | LIPGLPLFFAR1F11GSK3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250282728-A1 | NITROGEN COMPRISING HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF DISORDERS ASSOCIATED WITH GPR55 RECEPTOR | CEREVANCE INC (US) | 2025-09-11 | — | — | US | disclosed |
| WO-2023209368-A1 | NITROGEN COMPRISING HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF DISORDERS ASSOCIATED WITH GPR55 RECEPTOR | Cerevance, Inc. (US) | 2023-11-02 | — | — | WO | disclosed |
| WO-2023209368-A1 | NITROGEN COMPRISING HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF DISORDERS ASSOCIATED WITH GPR55 RECEPTOR | Cerevance, Inc. (US) | 2023-11-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250282728-A1 | NITROGEN COMPRISING HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF DISORDERS ASSOCIATED WITH GPR55 RECEPTOR | GPR55, GPR68, GPR65 | LIPG 1956/4885LPL 2320/4885FFAR1 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.